According to a report published by the Cancer Advocacy Coalition of Canada, lymphoma is the most common blood cancer, the sixth most common cause of cancer death, and the most common cancer for young people under 30 years of age in Canada. Although primary treatment with front-line combination chemotherapy can result in durable response rates, up to 30 percent of Hodgkin lymphoma and over 50 percent of systemic ALCL patients relapse or are refractory to front-line treatment and have few therapeutic options beyond ASCT.About ADCETRIS ADCETRIS received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2011 and was granted conditional marketing authorization by the European Commission in October 2012 and by Health Canada in February 2013 for relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. ADCETRIS is being evaluated across many disease settings in ongoing clinical trials in Canada, including a planned phase I/II investigator-sponsored clinical trial evaluating ADCETRIS in combination with bendamustine for patients with HL and ALCL that has either relapsed or did not respond to initial treatment. ADCETRIS is not currently approved for use in combination with bendamustine for patients with HL and ALCL that has either relapsed or did not respond to initial treatment. Seattle Genetics and Millennium are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs. About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company’s lead program, ADCETRIS (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional approval from the European Commission in October 2012. Seattle Genetics also has three other clinical-stage antibody-drug conjugate (ADC) programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at www.seattlegenetics.com. Certain of the statements made in this press release are forward looking, such as those, among others, relating to additional approvals of, reimbursement for and of the potential of clinical trials of ADCETRIS. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the inability to show sufficient activity in additional trials and the risk of adverse events as ADCETRIS advances in clinical trials or as a marketed product. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company’s 10-Q for the quarter ended September 30, 2012 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.